VJHemOnc is committed to improving our service to you

ASCO 2019 | MRD: venetoclax vs. BTK-inhibitors for CLL

VJHemOnc is committed to improving our service to you

Susan O’Brien

Susan O’Brien, MD, of the University of California Irvine, Irvine, CA, discusses how MRD impacts the choice of different treatments for chronic lymphocytic leukemia (CLL), specifically mentioning venetoclax and BTK-inhibitors. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter